Volume 16, Number 2—February 2010
Research
Tropheryma whipplei in Patients with Pneumonia
Sabri Bousbia, Laurent Papazian, Jean-Pierre Auffray, Florence Fenollar, Claude Martin, Wenjun Li, Laurent Chiche, Bernard La Scola, and Didier Raoult
Table 2
Demographic and clinical data on 6 intensive care unit patients with pneumonia from whom bronchoalveolar lavage samples positive for Tropheryma whipplei DNA were collected, Marseille, France, February 2007–January 2008*
| Specimen no. | Patient age, y/sex | Immunocompromised | Diagnosis | Type of pneumonia | Duration of MV, d | Duration of ICU stay, d | T. whipplei genotype | Outcome |
|---|---|---|---|---|---|---|---|---|
| 5 | 39/M | Yes (chemotherapy) | Septic shock | CAP | 7 | 10 | New | Survived |
| 10 | 46/M | Yes (splenectomy) | Coma | Aspiration | 3 | 5 | 3 | Survived |
| 82 | 65/M | No | Coma | Aspiration | 16 | 27 | New | Survived |
| 86 | 74/M | No | Pulmonary embolism | VAP | 42 | 42 | New | Died |
| 183 | 43/M | No | Pancreatitis | VAP | 14 | 16 | New | Survived |
| 209 | 74/M | Yes (corticosteroids) | Spinal cord injury | Aspiration | 81 | 81 | ND | Died |
*MV, mechanical ventilation; ICU, intensive care unit; CAP, community-acquired pneumonia; VAP, ventilator-associated pneumonia; ND, not determined.
†Based on 4 highly variable genomic sequences.
Page created: December 10, 2010
Page updated: December 10, 2010
Page reviewed: December 10, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.